Rite Aid Corp (RAD)
$9.64
0.20 (2.03%)
RAD Stock Quote Delayed 15 Minutes
Previous Close
$9.64
Market Cap
10.28B
PE Ratio
-28.35
EPS
-0.34
Volume (Avg. Vol.)
1.66M
Day's Range
9.45 - 10.05
52-Week Range
0.43 - 11.58
Dividend & Yield
N/A (N/A)
RAD Stock Predictions, Articles, and Rite Aid Corp News
Even With New CEO, Debt-Laden Rite Aid Stock is Best Avoided for Near Term
RAD stock hasn't benefited when management gave up selling electronic cigarettes while taking on CBD products. That's not the turnaround strategy it needs.
The Comfort Zone Is Holding Rite Aid Stock Back
Believe it or not, Rite Aid has the opportunity to maximize its revenue profile. But getting there is a herculean task, leaving Rite Aid stock an avenue best left for speculators.
The Roller Coaster Ride of Rite Aid Stock Is Much Ado About Nothing
RAD stock both rallied by 50% and dropped by 30% in September - and none of it had anything to do with the fundamentals of Rite Aid stock, which remain bad.
There’s No Management Turnaround That Will Boost Rite Aid Stock
Rite Aid stock – don’t wait for any management-led turnaround. This pharmacy retailer is laden with debt, cash flow losses and no clear turnaround plan.
Are Health Plans the Key to Rite Aid’s Savior?
Rather than trying desperately to find a buyer, Rite Aid will leverage their core strengths to bring value-add to their business. This is probably the best play available for Rite Aid stock.
With Any Turnaround Already Priced In, Avoid Rite Aid Stock
With this in mind, the stock is a hard pass. Investors likely can find more solid turnaround plays elsewhere. Given the volatility in the RAD stock prices, shares could shoot higher on speculation. But long term, Rite Aid stock is not a strong investment opportunity.
The Q2 Earnings Bump Is Not a Signal to Buy Rite Aid Stock
Rite Aid (NYSE:RAD) jumped more than 20% last week after exceeding second-quarter earnings guidance. The boost came at a good time. Rite Aid stock has....
Rite Aid Earnings: RAD Stock Soars 5% on Q2 Beat
Rite Aid (RAD) earnings for the second quarter of fiscal 2020 have RAD stock taking off on Thursday on a strong EPS beat.
For Q2 Earnings, Rite Aid Stock Must Bank on Positive Guidance
With Rite Aid reporting Q2 earnings on Thursday, all eyes will focus on the pharmacy retailer’s forward guidance. Unfortunately, that might not be a good thing for RAD stock.
A New CEO is One Reason Why Rite Aid’s Long-Term Prospects are Improving
Rite Aid stock has a chance of recovering but the new CEO has plenty of work ahead. The company must grow prescription volumes and sales.
Stock Market Today: Sleepy Session as Earnings Lurk Ahead
It was a slow session in the stock market today, with little gains showing up on Monday. Here's what happened in the U.S. stock market.
New CEO Heyward Donigan Needs a Miracle to Revive Rite Aid Stock
RAD stock looks tempting here in the midst of this lull, but what Rite Aid needs to do the most is the one thing that will be toughest to do.
Why Rite Aid Stock Will Probably Underperform Alternatives
With the RAD stock price down 95%, value investors might be intrigued. But there are better risk-adjusted plays than Rite Aid stock.
For Rite Aid Stock, Everything Depends on Millennials
As with most investments, the future of Rite Aid stock depends on millennials. Here, new Rite Aid CEO Heyward Donigan has both an opportunity as well as significant risks.
Even After Recent Gains Rite Aid Stock Is Still Underweight
Despite its cheap price, Rite Aid stock is hardly what you would call a discount. Instead, it’s a junk equity that you should steer clear from, considering that it doesn’t have an Amazon Counter-like catalyst in the foreseeable future.
It’s Still Too Risky to Bet on Rite Aid Stock
RAD stock is coming off of its best seven-day stretch in five years, but this rally may mean nothing in Rite Aid's bigger picture.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
D
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
